Controlled release of highly soluble agents

A drug and sustained-release technology, applied in the field of delivering sustained-release preparations and treating glaucoma, can solve problems such as inappropriate preparations and administration

Inactive Publication Date: 2006-03-01
控释给药系统公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Many therapeutic drugs are most readily available as salts that are highly soluble in water and, therefore

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Controlled release of highly soluble agents
  • Controlled release of highly soluble agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0080] Particles (1.5 mm in diameter, 2.0 mg) comprising D,L-lactide-co-glycolide (PLGA) and bovine albumin (1:1, w:w) were manually compressed. The particles were then dip-coated in a solution of PLGA / PEG (polyethylene glycol) in acetone and air dried. The dried coated particles were then embedded in a silicone array and covered by silicone, leaving 0.59mm diameter pores uncovered by silicone to allow albumin to diffuse.

[0081] The particles were placed in 1.0 ml of phosphate buffer (pH 7.4) and tested for release at 37°C. Samples were taken periodically and analyzed for albumin by HPLC.

[0082] figure 1 Cumulative release profile of particles coated with PLGA / PEG(8 / 2) is shown.

Embodiment 2

[0084]Particles (1.5 mm in diameter, 2.0 mg) comprising D,L-lactide-co-glycolide (PLGA) and bovine albumin (1:1, w:w) were manually compressed. The particles were then dip-coated in a solution of PLGA in acetone and air-dried. The dried coated particles were then embedded in a silicone array and covered by silicone, leaving 0.59mm diameter pores uncovered by silicone to allow albumin to diffuse.

[0085] The particles were placed in 1.0 ml of phosphate buffer (pH 7.4) and tested for release at 37°C. Samples were taken periodically and analyzed for albumin by HPLC.

[0086] figure 2 Cumulative release graph representing PLGA-coated particles.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Solubilityaaaaaaaaaa
Login to view more

Abstract

The invention provides a device and method for treating and/or preventing raised intraocular pressure, such as that associated with glaucoma or the use of corticosteroids with adrenergic agents. The invention provides insertable sustained-release devices adapted to maintain a therapeutically effective concentration of one or more adrenergic agents for an extended period of time, and a method of use thereof.

Description

Background of the invention [0001] Various devices have been developed for the prolonged local release of drugs in living organisms. The advantage of such a device is that it provides high concentrations of the active compound at the location where it is required for activity, while maintaining low systemic concentrations of the same drug. In cases where the active compound is toxic, such as when the drug is a steroid or an antineoplastic compound, it is very important to keep systemic concentrations low. Likewise, maintaining high local concentrations of drugs is important in situations where effective treatment of disease states is at or near safe dosage ranges. [0002] Implantable pharmaceutical compositions have been developed that deliver compounds in a single dose and provide controlled delivery of such compounds. Specifically, in U.S. Patent 6,051,576, Ashton et al. describe the covalent linking of two or more drug compounds (parent drugs) to form drug compounds that...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/32A61K9/00A61K9/50A61K31/382A61K31/542A61L27/34A61L27/54A61L31/10A61L31/16
CPCA61L27/34A61K9/5031A61L2300/602A61L2300/21A61K9/0092A61L31/16A61K31/382A61L31/10A61K31/542A61L27/54A61L2300/436A61K9/0051A61P27/06A61K9/209A61K9/28
Inventor 保罗·阿什顿
Owner 控释给药系统公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap